Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update

Virax Biolabs Group Limited (NASDAQ:VRAX) was the recipient of a significant increase in short interest during the month of May. As of May 15th, there was short interest totaling 391,277 shares, an increase of 173.2% from the April 30th total of 143,206 shares. Approximately 16.4% of the company’s shares are sold short. Based on an average daily trading volume, of 5,873,723 shares, the days-to-cover ratio is currently 0.1 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Virax Biolabs Group in a research note on Wednesday, April 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $1.00.

Virax Biolabs Group Price Performance

Shares of NASDAQ:VRAX opened at $0.19 on Friday. Virax Biolabs Group has a 52-week low of $0.10 and a 52-week high of $1.14. The business’s 50 day moving average is $0.17 and its 200 day moving average is $0.28.

Virax Biolabs Group Company Profile

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates.